Alkem Laboratories · NSE: ALKEM · BSE: 539523
Q3 FY22 results · Oct–Dec 2021
Alkem Laboratories reported revenue from operations of ₹2,618.98 crore (up 13.0% from Q3 FY21) and net profit of ₹533.35 crore (up 15.0% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,618.98 | 2,318.05 | +13.0% | 2,799.99 | −6.5% |
| Other income | 53.52 | 96.40 | −44.5% | 41.96 | +27.6% |
| Total income | 2,672.50 | 2,414.45 | +10.7% | 2,841.95 | −6.0% |
| Profit before tax | 463.94 | 543.44 | −14.6% | 581.54 | −20.2% |
| Net profit for the period | 533.35 | 463.85 | +15.0% | 558.53 | −4.5% |
| Attributable to shareholders of the company | 525.66 | 450.96 | +16.6% | 544.26 | −3.4% |
| EPS, basic (₹) | 43.96 | 37.72 | +16.6% | 45.52 | −3.4% |
| Net margin (%) | 20.4 | 20.0 | 19.9 |
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,180.84 | 1,778.75 | +22.6% | 2,363.99 | −7.7% |
| Other income | 63.24 | 72.46 | −12.7% | 43.21 | +46.4% |
| Total income | 2,244.08 | 1,851.21 | +21.2% | 2,407.20 | −6.8% |
| Profit before tax | 469.81 | 456.78 | +2.9% | 568.73 | −17.4% |
| Net profit for the period | 437.09 | 400.98 | +9.0% | 558.01 | −21.7% |
| EPS, basic (₹) | 36.56 | 33.54 | +9.0% | 46.67 | −21.7% |
| Net margin (%) | 20.0 | 22.5 | 23.6 |
Consolidated
- Filed with BSE
- 04 Feb 2022, 17:17 IST
- Board meeting
- 04 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 04 Feb 2022, 17:17 IST
- Board meeting
- 04 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE